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The increased understanding of immunoregulatory recep-
tor pathways is now offering promising opportunities for
immunotherapeutic intervention, as exemplified by the
success of anti-CTLA-4 antibody (Ab) Ipilimumab. More
recently, an agonist Ab for the co-stimulatory receptor
glucocorticoid-induced TNF receptor (GITR) has entered
the clinical evaluation. Preclinical studies have well docu-
mented the therapeutic efficacy of GITR ligation using the
agonist Ab DTA-1. However, as a monotherapy, it is no
longer effective against advanced B16 melanoma. As anti-
GITR immunotherapy is being translated into the clinic,
understanding the mechanisms of therapeutic efficacy or
failure is warranted, and will allow the identification of
prognostic biomarkers and guide the design of combina-
tion therapies. To this end, we first studied the phenotypic
and functional modulations of T cells, either effector
(Teff) or regulatory T cells (Tregs), when co-cultured in
vitro with B16F10 cells in the presence of DTA-1. We sub-
sequently verified whether the in vitro DTA-1-induced
modulations occurred at a different extent in vivo when
tumor-bearing mice were treated in curative or refractory
conditions.
In vitro DTA-1-preincubated Tregs lost their immu-
nosuppressive activity without any modulation in the
Treg-associated transcription factors Foxp3 and Helios.
Accordingly, DTA-1-treated Treg cultures showed an
increased production of IFNg, TNF-alpha, TGF-beta, IL-
17 and IL-6, pointing to the promotion of a Th1/Th17
differentiation profile following GITR engagement. In
vivo analysis of B16F10 microenvironment shows a
reduction in Teff activation status, and an increase in
the frequency of Tregs, as well as their expression of
Foxp3, CD25 and OX40, in more advanced disease. Simi-
larly, MHC-II was expressed at significantly lower levels in
advanced tumors. Interestingly, DTA-1 treatment reduced
the frequency of tumor-infiltrating Tregs and their expres-
sion of Foxp3 and Helios either in curative or refractory
condition (advanced tumors). By contrast, Teff activation
and tumor-associated MHC-II expression were induced
only by optimal DTA-1 treatment.
Our data indicate that DTA-1 affects tumor-induced
immune-tolerance independently from the stage of the
disease, whereas T-cell activation and tumor immune
recognition are favored selectively in the presence of low
tumor burden. This provides the rationale for studying
DTA-1 therapy in combination with strategies that can
promote Teff functions and/or directly affect the tumor
burden, such as blockade of immune checkpoints (anti-
CTLA-4 and anti-PD-1 Abs), stimulation of other co-
stimulatory molecules, or targeted therapies and radiation
therapy.
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